Join IDEAYA Biosciences for an investor webcast to provide a clinical data update for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha (MAT2A) inhibitor in Phase 2 clinical trials for the treatment of methylthioadenosine phosphorylase (MTAP) deletion solid tumors.

The investor webcast presentation agenda to review the IDE397 clinical data update of the Phase 2 expansion dose results in MTAP-deletion urothelial and NSCLC patients will be the following:

• Market introduction: U.S. annual incidence in MTAP-deletion solid tumors
• IDE397 preclinical summary in MTAP-deletion
• Patient baseline characteristics
• Pharmacokinetics and pharmacodynamics
• Adverse event profile
• Clinical efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC patients by RECIST 1.1
  • Overall Response Rate (%ORR) and Disease Control Rate (%DCR) analysis
  • Swimlane plot
  • ctDNA molecular response analysis
  • Case reports and CT-scan images

The IDEAYA speakers will include Yujiro S. Hata, Chief Executive Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer.